# Lipocine Inc.: overview LPCN · Nasdaq · CIK 1535955 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/lpcn.md) · [Financials](/companies/lpcn/financials.md) · [Filings](/companies/lpcn/filings.md) · [Insiders](/companies/lpcn/insiders.md) Latest reported revenue: [$190.1k](/filings/0001493152-26-035909.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:Revenues, accession 0001493152-26-035909). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0 d](/filings/0001493152-25-021007.md) | [3,491 d](/filings/0001493152-26-009411.md) | [93.9](/filings/0001493152-26-021637.md) | [623](/filings/0001493152-26-035909.md) | [115](/filings/0001493152-25-021007.md) | [1,145 d](/filings/0001493152-26-009411.md) | [119](/filings/0001493152-26-021637.md) | [190](/filings/0001493152-26-035909.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [44.3% d](/filings/0001493152-26-009411.md) | [(2226.8%)](/filings/0001493152-26-021637.md) | [(386.0%)](/filings/0001493152-26-035909.md) | [(2933.5%)](/filings/0001493152-25-021007.md) | [(219.6%) d](/filings/0001493152-26-009411.md) | [(3224.1%)](/filings/0001493152-26-021637.md) | [(1495.1%)](/filings/0001493152-26-035909.md) | | Net margin | % | not reported | [51.0% d](/filings/0001493152-26-009411.md) | [(1986.8%)](/filings/0001493152-26-021637.md) | [(354.1%)](/filings/0001493152-26-035909.md) | [(2781.5%)](/filings/0001493152-25-021007.md) | [(206.9%) d](/filings/0001493152-26-009411.md) | [(3075.4%)](/filings/0001493152-26-021637.md) | [(1379.6%)](/filings/0001493152-26-035909.md) | | Diluted EPS | $ per share | [(0.44)](/filings/0001493152-25-021007.md) | not reported | [(0.35)](/filings/0001493152-26-021637.md) | [(0.41)](/filings/0001493152-26-035909.md) | [(0.59)](/filings/0001493152-25-021007.md) | not reported | [(0.54)](/filings/0001493152-26-021637.md) | [(0.32)](/filings/0001493152-26-035909.md) | | Free cash flow | $k | not reported | [1,692 d](/filings/0001493152-26-009411.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [16.1](/filings/0001493152-23-007178.md) | [0.5](/filings/0001493152-23-007178.md) | [(2.9)](/filings/0001493152-25-010146.md) | [11.2](/filings/0001493152-26-009411.md) | [2.0](/filings/0001493152-26-009411.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [19.5%](/filings/0001493152-23-007178.md) | [(2423.9%)](/filings/0001493152-24-009127.md) | [629.0%](/filings/0001493152-25-010146.md) | [(10.3%)](/filings/0001493152-26-009411.md) | [(524.7%)](/filings/0001493152-26-009411.md) | | Net margin | % | [(3.9%)](/filings/0001493152-23-007178.md) | [(2151.7%)](/filings/0001493152-24-009127.md) | [573.6%](/filings/0001493152-25-010146.md) | [0.1%](/filings/0001493152-26-009411.md) | [(487.1%)](/filings/0001493152-26-009411.md) | | Diluted EPS | $ per share | [(0.01)](/filings/0001493152-23-007178.md) | [(2.15)](/filings/0001493152-24-009127.md) | [(3.14)](/filings/0001493152-25-010146.md) | not reported | [(1.69)](/filings/0001493152-26-009411.md) | | Free cash flow | $m | [(4.4)](/filings/0001493152-23-007178.md) | [(12.1)](/filings/0001493152-24-009127.md) | [(11.9)](/filings/0001493152-25-010146.md) | [(1.3)](/filings/0001493152-26-009411.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lpcn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Squadron Capital Management LLC](/funds/2050709.md) | 2026-06-30 | $2.1m | 810,000 | | Added +360,000 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $1.3m | 508,556 | | Unchanged | | [Eversept Partners, LP](/funds/1697013.md) | 2026-06-30 | $755.2k | 294,989 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $590.9k | 230,823 | | Added +30,155 | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $359.6k | 140,487 | | Unchanged | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $243.8k | 95,227 | | Added +75,200 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $228.5k | 89,272 | | Unchanged | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $217.3k | 84,887 | | Added +51,137 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $207.9k | 81,221 | | Added +52,133 | | [Seven Fleet Capital Management LP](/funds/2092021.md) | 2026-06-30 | $201.8k | 78,842 | | Reduced −46,100 | ## Recent filings [All 818 filings](/companies/lpcn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 11:46 ET | [8-K](/filings/0001493152-26-047693.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-047693 | | 2026-10-07 | 10:10 ET | [8-K](/filings/0001493152-26-046060.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-046060 | | 2026-09-16 | 20:38 ET | [8-K](/filings/0001493152-26-042933.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-042933 | | 2026-09-14 | 10:15 ET | [8-K](/filings/0001493152-26-042466.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-042466 | | 2026-09-11 | 10:10 ET | [8-K](/filings/0001493152-26-042286.md) | 8.01 Other events | 0001493152-26-042286 | | 2026-09-10 | 10:14 ET | [8-K](/filings/0001493152-26-042052.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-042052 | | 2026-08-21 | 20:30 ET | [8-K/A](/filings/0001493152-26-039689.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-039689 | | 2026-08-04 | 10:08 ET | [8-K](/filings/0001493152-26-035913.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-035913 | | 2026-08-04 | 10:03 ET | [10-Q](/filings/0001493152-26-035909.md) | Quarterly report, period 2026-06-30 | 0001493152-26-035909 | | 2026-08-03 | 13:35 ET | [8-K](/filings/0001493152-26-035762.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-035762 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-009411.md), filed Mar 10, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d8a33038-b0f4-4a9a-bbd3-09e2c5f01f68) ## About the filer - CIK: 1535955 - Tickers: LPCN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.